TAG:

xifin

XIFIN’s Acquisition of OmniSYS Will Unite Lab with Pharmacy

This is an excerpt of a 1,829-word article in the January 10, 2022 issue of  THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: XIFIN’s acquisition of OmniSys, a pharmacy technology company, is the latest evidence that …

Read More



2021 Closes with Two Major Lab Industry Events

Normally, the time around Christmas and New Year passes quietly, typically without any significant developments. Such was not the case for the clinical laboratory industry in the last month of 2021 because of two announcements, each of which confirms ongoing market trends in healthcare and the lab te…

Read More



XIFIN Buys OmniSYS, Bridges Lab to Pharmacy

CEO SUMMARY: XIFIN’s acquisition of pharmacy technology company OmniSYS is the latest evidence that retail pharmacies are preparing to become a new front door to healthcare for consumers. The deal allows XIFIN to bring clinical lab information about patients directly to pharmacist…

Read More



Labs, Pathology Groups Face Reduced Revenue

CEO SUMMARY: In recent years, certain clinical laboratories and pathology groups found they can generate more revenue by remaining out of network whenever possible. But when the No Surprises Act goes into effect Jan. 1, labs and pathologists may find advantages in being in network. …

Read More



Payers Continue to Increase Coverage of Liquid Biopsies

SINCE THE FIRST BLOOD-BASED, circulating-tumor DNA (ctDNA) sequencing test for cancer became available in 2014, federal and private payer coverage of these so-called “liquid biopsy” tests has increased substantially. Now, clinical laboratory and pathology directors can expect additional coverage …

Read More



Comment Period Closing on Federal Surprise Billing Rule

PATHOLOGY GROUPS AND CLINICAL LABS HAD UNTIL SEPTEMBER 7 to comment on an interim final rule that provides federal protections against surprise billing and limits out-of-network (OON) cost sharing under many of the circumstances in which surprise bills arise most frequently….

Read More



September 7, 2021 Intelligence: Late-Breaking Lab News

New diagnoses of cancer in the United States fell by almost 30% in the early months of the SARS-CoV-2 pandemic. That’s one conclusion in a paper authored by Quest Diagnostics and published on Aug. 31, in JAMA Network Open. Quest looked at the new diagnoses of eight common types of can…

Read More



How to Achieve Success with Genetic Test Prior Authorization

AS MANAGED CARE PAYERS INCREASINGLY REQUIRE PRIOR AUTHORIZATION FOC GENETIC TESTS, clinical laboratories should understand the ins and outs of what it takes to get reimbursed for testing they provide.  Almost all payers now require prior authorization (P…

Read More



XIFIN to Open New Office in South Carolina for Lab Billing

SINCE FEBRUARY, THE TOTAL NUMBER OF PEOPLE VACCINATED grew steadily even as the number of tests for COVID-19 declined sharply in the United States. But overall test volume has remained steady at 130% of pre-pandemic levels, said Brian Kemp, Vice President of Revenue Cycle Operations for XIFIN,…

Read More



Benefits Investigation Is Growing Issue for Genetic Testing Labs

QUIETLY AND WITH LITTLE NEWS COVERAGE, a new complication is challenging clinical laboratories that offer genetic testing. It involves a steady growth in the number of patients who do a “benefits investigation” before allowing their physician to order a genetic test….

Read More



;